Dyadic International Inc. (DYAI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
Dyadic International, Inc. ( DYAI ) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Company Participants Ping Rawson - Chief Financial Officer Joseph Hazelton - President & COO Mark Emalfarb - Founder, CEO & Director Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division John Vandermosten - Zacks Small-Cap Research Robert Hoffman Tony Bowers Presentation Operator Good evening, and welcome to Dyadic International's Q3 2025 Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, November 12, 2025.
Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Joseph P. Hazelton - President & COO Mark A.
Dyadic International Inc. (DYAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dyadic International Inc. ever had a stock split?
Dyadic International Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark A. Emalfarb CEO | NASDAQ (CM) Exchange | 26745T101 CUSIP |
| US Country | 6 Employees | - Last Dividend | - Last Split | 5 Nov 2004 IPO Date |
Overview
Dyadic International, Inc. is a trailblazer in the biotechnology sector, focusing on the development, production, and commercialization of enzymes and other proteins for a wide range of applications. With its operations spanning both the United States and international markets, the company has carved out a niche in leveraging advanced biotechnology for the betterment of human and animal health. Central to Dyadic's innovative approach is its C1-cell protein production platform. This technology harnesses the power of an industrially proven microorganism, known as C1, to revolutionize the way biologic products, including critical enzymes and proteins, are developed and manufactured. Founded in 1979 and based in Jupiter, Florida, Dyadic International is committed to pushing the frontiers of biotechnology to address pressing health challenges and improve the quality of life globally. Its strategic collaborations and licensing agreements with leading research and commercial organizations worldwide underscore its prominence in the biotech industry.
Products and Services
- DYAI-100: SARS-CoV-2-RBD Antigen Vaccine Candidate
As part of its innovative product lineup, Dyadic International has developed DYAI-100, a highly anticipated antigen vaccine candidate targeting SARS-CoV-2, the virus responsible for COVID-19. This groundbreaking vaccine candidate signifies a major leap in the fight against the pandemic, as it is ready to undergo a first-in-human Phase 1 clinical trial. The trial aims to validate the safety of the protein produced using the distinct C1 platform, showcasing Dyadic's commitment to leveraging its proprietary technology for tackling global health crises.
- Dapibus Thermophilic Microbial Protein Production Platform
In addition to its pharmaceutical applications, Dyadic has ventured into non-pharmaceutical fields with the creation of the Dapibus thermophilic platform. This novel platform is based on a filamentous fungal technology designed to facilitate the development and large-scale manufacturing of proteins, metabolites, and other biologic products at cost-effective rates. Targeting industries such as food, nutrition, and wellness, the Dapibus platform exemplifies Dyadic's versatile application of microbial protein production technologies to meet a wide array of global needs.
Contact Information
